Short answer
HERON THERAPEUTICS, INC. /DE/ (HRTX) filed an 8-K current report with the SEC on September 29, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Exclusive U.S. commercialization rights for multiple products, with sublicensing and worldwide manufacturing rights.
HERON THERAPEUTICS, INC. /DE/ 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Exclusive U.S. commercialization rights for multiple products, with sublicensing and worldwide manufacturing rights
- Regulatory and sales milestones, royalties, and expense reimbursements create future cash obligations tied to product performance
- Ten-year initial term begins after first commercial sale, with automatic two-year renewals
- Capstone provides exclusivity covenants and backstop obligations, strengthening contractual support for the arrangement
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other HERON THERAPEUTICS, INC. /DE/ 8-K filings
Get the next HRTX 8-K as it lands
Follow HRTX for push alerts, or ask the research agent what this filing means.